Cantor Fitzgerald Reaffirms "Overweight" Rating for MiMedx Group (NASDAQ:MDXG)

Cantor Fitzgerald reiterated their overweight rating on shares of MiMedx Group (NASDAQ:MDXG - Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $11.00 price target on the stock.

Separately, Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "buy" rating in a report on Friday, June 6th.

MiMedx Group Trading Down 4.5%

NASDAQ:MDXG traded down $0.30 during mid-day trading on Tuesday, reaching $6.42. The company's stock had a trading volume of 669,080 shares, compared to its average volume of 669,494. The company's fifty day simple moving average is $6.49 and its two-hundred day simple moving average is $7.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.70 and a quick ratio of 4.13. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $10.14. The stock has a market cap of $948.23 million, a P/E ratio of 23.78 and a beta of 1.76.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a return on equity of 22.70% and a net margin of 11.40%. The firm had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. On average, equities analysts predict that MiMedx Group will post 0.3 EPS for the current year.

Insider Buying and Selling

In other MiMedx Group news, CEO Joseph H. Capper bought 200,000 shares of the business's stock in a transaction on Friday, May 2nd. The shares were bought at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the transaction, the chief executive officer directly owned 529,530 shares in the company, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.70% of the company's stock.

Hedge Funds Weigh In On MiMedx Group

A number of institutional investors have recently made changes to their positions in the business. Truist Financial Corp grew its position in shares of MiMedx Group by 80.8% in the 2nd quarter. Truist Financial Corp now owns 96,250 shares of the company's stock worth $588,000 after acquiring an additional 43,000 shares in the last quarter. HB Wealth Management LLC acquired a new position in shares of MiMedx Group in the 2nd quarter worth approximately $156,000. Harbor Capital Advisors Inc. grew its position in shares of MiMedx Group by 12.0% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 1,169,195 shares of the company's stock worth $7,144,000 after acquiring an additional 125,519 shares in the last quarter. Rhumbline Advisers grew its position in shares of MiMedx Group by 1.4% in the 1st quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock worth $1,346,000 after acquiring an additional 2,436 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of MiMedx Group in the 1st quarter worth approximately $595,000. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.